SCHEMBL25000348

SCHEMBL25000348

c1ccc(-c2ccc(-c3ccc(N(c4cccc5c4oc4c(-c6ccccc6)cccc45)c4cccc5oc6ccccc6c45)cc3)cc2-c2ccccc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 2/20 0.39
▸ CDC14B O60729 2/20 0.35
▸ CDC14A Q9UNH5 2/20 0.35
▸ PLA2G2A P14555 4/20 0.34
▸ PLA2G4A P47712 4/20 0.34
▸ PRKDC P78527 4/20 0.33
▸ PLA2G10 O15496 1/20 0.33
▸ GGPS1 O95749 1/20 0.32
▸ TNKS O95271 2/20 0.31
▸ PTGES2 Q9H7Z7 1/20 0.31
▸ TP53 P04637 2/20 0.30
▸ CYP3A4 P08684 2/20 0.30
▸ SMN1; SMN2 Q16637 2/20 0.30
▸ GABRP O00591 1/20 0.30
▸ GABRD O14764 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ CA12 O43570 1/20 0.30
▸ CA1 P00915 1/20 0.30
▸ CA2 P00918 1/20 0.30
▸ ABCB1 P08183 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25629066 0.96 ALOX5 (0.40) ALOX5CDC14BCDC14APLA2G2APLA2G4A
SCHEMBL25000212 0.94 ALOX5 (0.38) ALOX5CDC14BCDC14APLA2G2APLA2G4A
SCHEMBL24999272 0.93 ALOX5 (0.44) ALOX5CDC14BCDC14APLA2G2APLA2G4A
SCHEMBL25621507 0.92 ALOX5 (0.41) ALOX5CDC14BCDC14APLA2G2APLA2G4A
SCHEMBL25629067 0.91 PRKDC (0.38) ALOX5PLA2G2APLA2G4APRKDCTP53
SCHEMBL25621206 0.89 ALOX5 (0.44) ALOX5CDC14BCDC14APLA2G2APLA2G4A
SCHEMBL25550906 0.89 PLA2G2A (0.35) ALOX5CDC14BCDC14APLA2G2APLA2G4A
SCHEMBL25000330 0.89 ALOX5 (0.47) ALOX5CDC14BCDC14APLA2G2APLA2G4A
SCHEMBL24999257 0.89 PLA2G2A (0.37) ALOX5CDC14BCDC14APLA2G2APLA2G4A
SCHEMBL22523696 0.89 ALOX5 (0.42) ALOX5CDC14BCDC14APLA2G2APLA2G4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230200222-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-22 — — US disclosed
US-20230200222-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-22 — — US disclosed
US-11678569-B2 Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2023-06-13 — — US disclosed
US-11678569-B2 Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2023-06-13 — — US disclosed
EP-4129972-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE Idemitsu Kosan Co.,Ltd. (JP) 2023-02-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230200222-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE PIEZO1, LEF1, L1CAM ALOX5 1914/4885CDC14B 4318/4885CDC14A 4255/4885
US-11678569-B2 Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device PIEZO1, LEF1, L1CAM ALOX5 1914/4885CDC14B 4318/4885CDC14A 4255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback